
Novavax NVAX
$ 8.7
5.45%
Quarterly report 2025-Q3
added 11-06-2025
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
152 M |
Market Cap[1] |
$ 1.32 B |
EBITDA (LTM) |
$ -17.9 M |
P/E (LTM) |
4.64 |
P/S (LTM) |
1.24 |
EPS (LTM) |
1.87 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
ANI Pharmaceuticals
ANIP
|
$ 80.34 | -1.83 % | $ 1.55 B | Nasdaq Global Market,SPB | ||
|
Aptorum Group Limited
APM
|
$ 0.84 | 3.54 % | $ 4.58 M | Nasdaq Global Select Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Adagene
ADAG
|
$ 2.67 | 1.52 % | $ 150 M | Nasdaq Global Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.57 | 1.13 % | $ 8.59 B | Nasdaq Capital Market | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
BioNTech SE
BNTX
|
$ 110.34 | 3.49 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Cabaletta Bio
CABA
|
$ 2.44 | -2.79 % | $ 2.85 M | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 4.22 | 1.44 % | $ 9.18 B | NYSE American | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Akebia Therapeutics
AKBA
|
$ 1.5 | 7.91 % | $ 281 M | Nasdaq Global Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Ascendis Pharma A/S
ASND
|
$ 222.03 | -0.05 % | $ 5 B | Nasdaq Global Select Market | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
Compugen Ltd.
CGEN
|
$ 1.71 | 2.4 % | $ 153 M | Nasdaq Global Market,SPB | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Burford Capital Limited
BUR
|
$ 8.97 | 0.56 % | $ 1.43 B | NYSE | ||
|
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
Corcept Therapeutics Incorporated
CORT
|
$ 41.31 | 1.18 % | $ 4.26 B | Nasdaq Capital Market,SPB | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Catalyst Pharmaceuticals
CPRX
|
$ 24.45 | 0.04 % | $ 2.9 B | Nasdaq Capital Market | ||
|
Cardiff Oncology
CRDF
|
$ 1.58 | -1.25 % | $ 75.3 M | Nasdaq Capital Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 49.7 | 1.97 % | $ 4.19 B | Nasdaq Global Market,SPB | ||
|
Champions Oncology
CSBR
|
$ 6.55 | - | $ 89.5 M | Nasdaq Capital Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.46 | 2.82 % | $ 373 M | Nasdaq Global Select Market | ||
|
Amneal Pharmaceuticals
AMRX
|
$ 14.52 | - | $ 4.49 B | NYSE |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.